EXOZYMES INC. Operating Income
EXOZYMES INC. (EXOZ) reported Operating Income of -$2.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- EXOZYMES INC. operating income (loss) for the quarter ending 2026-06-30 was -$2.95M.
- EXOZYMES INC. operating income (loss) for the quarter ending 2026-03-31 was -$2.39M.
- EXOZYMES INC. operating income (loss) for the quarter ending 2025-12-31 was -$2.70M.
- EXOZYMES INC. operating income (loss) for the quarter ending 2025-09-30 was -$2.52M.
- EXOZYMES INC. operating income (loss) for fiscal 2025 was -$9.72M.
- EXOZYMES INC. operating income (loss) for fiscal 2024 was -$5.93M.
- EXOZYMES INC. operating income (loss) for fiscal 2023 was -$1.80M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.95M 10-Q · filed 2026-08-13 | -$5.34M 10-Q · filed 2026-08-13 | -$8.04M derived: sum of 3 quarters · filed 2026-08-13 | -$10.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.39M 10-Q · filed 2026-05-14 | -$5.08M derived: sum of 2 quarters · filed 2026-05-14 | -$7.60M derived: sum of 3 quarters · filed 2026-05-14 | -$10.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$5.22M derived: sum of 2 quarters · filed 2026-03-30 | -$7.77M derived: sum of 3 quarters · filed 2026-08-13 | -$9.72M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.52M 10-Q · filed 2025-11-13 | -$5.07M derived: sum of 2 quarters · filed 2026-08-13 | -$7.02M 10-Q · filed 2025-11-13 | -$9.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.55M 10-Q · filed 2026-08-13 | -$4.50M 10-Q · filed 2026-08-13 | -$6.48M derived: sum of 3 quarters · filed 2026-08-13 | -$8.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.95M 10-Q · filed 2026-05-14 | -$3.93M derived: sum of 2 quarters · filed 2026-05-14 | -$5.55M derived: sum of 3 quarters · filed 2026-05-14 | -$6.87M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.60M derived: sum of 2 quarters · filed 2026-03-30 | -$4.92M derived: sum of 3 quarters · filed 2026-03-30 | -$5.93M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$1.61M 10-Q · filed 2025-11-13 | -$2.94M derived: sum of 2 quarters · filed 2025-11-13 | -$3.95M 10-Q · filed 2025-11-13 | -$4.93M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.33M 10-Q · filed 2025-08-12 | -$2.34M 10-Q · filed 2025-08-12 | -$3.32M derived: sum of 3 quarters · filed 2025-08-12 | -$3.71M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.01M 10-Q · filed 2025-05-12 | -$1.99M derived: sum of 2 quarters · filed 2025-05-12 | -$2.39M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$985.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.38M derived: sum of 2 quarters · filed 2025-03-31 | -$1.80M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$391.85K 10-Q · filed 2024-11-12 | -$811.17K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |